Last Updated : April 30, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo-Yervoy | nivolumab-ipilimumab | Malignant Pleural Mesothelioma (MPM) | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdualag | nivolumab and relatlimab | unresectable or metastatic melanoma | Reimburse with clinical criteria and/or conditions | Active | ||
Opsumit | Macitentan | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete | ||
Opsynvi | macitentan and tadalafil | Pulmonary arterial hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
Oralair | Grass Pollen Allergen Extract | Allergic rhinitis | List with criteria/condition | Complete | ||
Orencia | Abatacept | Arthritis, rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Orencia | Abatacept | Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
Orencia | Abatacept | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete |